A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03626012
• Other study ID #: 245AS101
• Secondary ID: 2017-000294-36
• Status: Completed
• Phase: Phase 1
• Start date: September 10, 2018
• Est. completion date: November 17, 2021

Study information

• Verified date: January 2022
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-Amyotrophic Lateral Sclerosis (ALS). The secondary objectives of this study are to evaluate the pharmacokinetic profile of BIIB078 and to evaluate the effects of BIIB078 on clinical function. As the first-in-human study, the study enrolls a small number of participants in each cohort. Every participant in a cohort is treated with the same dose or placebo. The study is designed to evaluate and confirm the safety of each dose before enrolling and exposing new participants to a higher dose in the next cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: November 17, 2021
• Est. primary completion date: November 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Ability of the participant to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information in accordance with national and local participant privacy regulations; or, in the event of the participant's physical incapacity to sign, to confirm that understanding and consent orally to a legally authorized representative (LAR) for the express purpose of having said informed consent and authorization signed on his/her behalf.

• All participants of childbearing potential must agree to practice highly effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.

• Must meet the possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria and have documentation of a clinical genetic test demonstrating the presence of a pathogenic mutation in C9ORF72.

• Slow vital capacity (SVC) = 50% of predicted value as adjusted for sex, age, and height (from the sitting position).

• Participants taking concomitant riluzole at study entry must be on a stable dose for = 30 days prior to the first dose of study treatment (Day 1).

• Participants taking concomitant edaravone at study entry must be on a stable dose for = 60 days prior to the first dose of study treatment (Day 1).

• ALS Cognitive Behavioral Screen (ALS-CBS) score = 11 for the cognitive portion; = 33 for the behavioral portion.

• Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.

• Screening values of coagulation parameters including platelet count, international normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (APTT) should be within normal ranges.

• Has an informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities at Screening.

Key Exclusion Criteria:

• History of drug abuse or alcoholism = 6 months of Screening that would limit participation in the study, as determined by the Investigator.

• Tracheostomy.

• Prescreening ALSFRS-R slope less than 0.4 points/month, where prescreening ALSFRS-R slope is defined as follows: (48 - ALSFRS-R score at Screening) / (months from date of symptom onset to date of Screening).

• History of or positive test result at Screening for human immunodeficiency virus. .

• History of, or positive test result at Screening for, hepatitis C virus antibody.

• Treatment with another investigational drug or biological agent within 1 month of Screening or 5 half-lives of study agent, whichever is longer.

• Treatment with an antiplatelet or anticoagulant therapy that cannot safely be interrupted for lumbar puncture (LP) according to local standard of care and/or institutional guidelines, in the opinion of the Investigator or Prescriber.

• Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period.

• Female participants who are pregnant or currently breastfeeding.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• BIIB078
Administered as specified in the treatment arm.
• Placebo
Administered as specified in the treatment arm.

Locations

Country	Name	City	State
Canada	Research Site	Calgary	Alberta
Canada	Research Site	Montreal	Quebec
Canada	Research Site	Toronto	Ontario
Ireland	Research Site	Dublin
Netherlands	Research Site	Utrecht
Switzerland	Research Site	St. Gallen
United Kingdom	Research Site	London	Greater London
United Kingdom	Research Site	London
United Kingdom	Research Site	Sheffield	South Yorkshire
United States	Research Site	Atlanta	Georgia
United States	Research Site	Baltimore	Maryland
United States	Research Site	Boston	Massachusetts
United States	Research Site	Jacksonville	Florida
United States	Research Site	Knoxville	Tennessee
United States	Research Site	La Jolla	California
United States	Research Site	Lincoln	Nebraska
United States	Research Site	Los Angeles	California
United States	Research Site	Miami	Florida
United States	Research Site	New York	New York
United States	Research Site	Palo Alto	California
United States	Research Site	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Canada,  Ireland,  Netherlands,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, places participant at immediate risk of death, requires initial or prolonged inpatient hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly, is a medically important event.	Baseline through End of Study (Approximately Day 323)
Secondary	Serum BIIB078 Concentration		Baseline and at multiple time points up to Day 260
Secondary	Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)		Baseline and at multiple time points up to Day 260
Secondary	AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)		Baseline and at multiple time points up to Day 260
Secondary	Maximum Observed Concentration (Cmax)		Baseline and at multiple time points up to Day 260
Secondary	Time to Reach Cmax (Tmax)		Baseline and at multiple time points up to Day 260
Secondary	Terminal Elimination Half-Life (t 1/2)		Baseline and at multiple time points up to Day 260
Secondary	Change from Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Scores	The ALSFRS-R has been demonstrated to predict survival. The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.	Baseline up to Day 323
Secondary	Change from Baseline in Percent of Predicted Slow Vital Capacity (SVC)		Baseline up to Day 260
Secondary	Change from Baseline in Muscle Strength	Quantitative muscle strength will be evaluated using hand-held dynamometry (HHD), which tests isometric strength of multiple muscles using standard participant positioning. Approximately 8 muscle groups will be examined (per each side) in both upper and lower extremities.	Baseline up to Day 260
Secondary	Change from Baseline in Bulbar Strength	Bulbar strength will be measured by the Iowa Oral Pressure Instrument (IOPI). The IOPI is a commercially available tongue pressure measurement system composed of an air-filled bulb connected to a pressure transducer. The bulb can be placed in different positions in the mouth in order to assess different aspects of tongue weakness.	Baseline up to Day 260